npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
International survey on invasive lobular breast cancer identifies priority research questions341
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers178
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer172
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells158
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?144
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients128
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer102
Biological correlates associated with high-risk breast cancer patients identified using a computational method95
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer93
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment89
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab74
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors70
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women68
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer67
Immunotherapy for early triple negative breast cancer: research agenda for the next decade67
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab65
The clinical and molecular significance associated with STING signaling in breast cancer65
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment59
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models55
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays54
Circulating tumor DNA validity and potential uses in metastatic breast cancer54
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice51
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)51
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer47
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC45
Survival outcomes after omission of surgery for ductal carcinoma in situ44
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer44
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer42
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer42
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer42
Temporal evolution of breast cancer brain metastases treatments and outcomes41
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases40
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis39
Is conservative management of ductal carcinoma in situ risky?38
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors38
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer38
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality38
Understanding metastasis mixed-treatment responses through genomic analyses36
Kataegis in clinical and molecular subgroups of primary breast cancer35
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer34
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center32
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer32
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling32
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program31
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment31
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature31
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin30
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies30
Radiation recall dermatitis following letrozole administration in patient with a remote history of radiation therapy30
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer29
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study29
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer29
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies28
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models28
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance28
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer28
Oncogene-mediated metabolic gene signature predicts breast cancer outcome27
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer27
Large language model (ChatGPT) as a support tool for breast tumor board27
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy26
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer26
Cook and Move for Your Life, an eHealth intervention for women with breast cancer26
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies25
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial25
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief25
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer25
Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study25
Randomized trial of weight loss on circulating ghrelin levels among breast cancer survivors25
A systematic review of determinants of breast cancer risk among women with benign breast disease25
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 25
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers24
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer24
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models24
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer24
Prognostic value of structural variants in early breast cancer patients24
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis24
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis24
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer23
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer23
Subclonal heterogeneity and evolution in breast cancer22
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women22
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases22
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy21
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation21
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence21
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study21
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer21
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer20
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor20
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women20
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study20
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape20
Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB120
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer19
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry19
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence19
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response19
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer19
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study19
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy18
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer18
Plasma C-peptide mammographic features and risk of breast cancer18
Racial discrimination among women seeking breast cancer care18
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer17
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib17
Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-117
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer17
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer17
Artificial intelligence in breast pathology – dawn of a new era17
Post-diagnosis weight trajectories and mortality among women with breast cancer17
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer16
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression16
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial16
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer16
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination16
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials16
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer16
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts16
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer15
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics15
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study15
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer15
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer15
MammOnc-DB, an integrative breast cancer data analysis platform for target discovery15
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer15
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings15
0.11381101608276